SuperGen Inc. has extended its research agreement with the Stehlin Foundation for Cancer Research to eight years. As part of this agreement, SuperGen also secured the global rights to other camptothecins and additional anticancer compounds. One of these compounds has already demonstrated marked antitumor activity and is expected to have a very favorable safety profile. Read more about Supergen And Stehlin Foundation Expand Research Agreement[…]